ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) fell 8.6% on Tuesday . The stock traded as low as $9.40 and last traded at $9.23. 2,148,828 shares traded hands during trading, a decline of 26% from the average session volume of 2,914,794 shares. The stock had previously closed at $10.10.
Wall Street Analysts Forecast Growth
Separately, Canaccord Genuity Group increased their price objective on ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a report on Wednesday, May 21st.
Get Our Latest Report on ASP Isotopes
ASP Isotopes Stock Performance
The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.17 and a current ratio of 7.21. The stock's 50-day simple moving average is $8.14 and its two-hundred day simple moving average is $6.26. The stock has a market cap of $792.02 million, a price-to-earnings ratio of -15.39 and a beta of 3.35.
Institutional Trading of ASP Isotopes
Several hedge funds have recently added to or reduced their stakes in ASPI. CenterBook Partners LP bought a new position in ASP Isotopes in the 4th quarter worth approximately $6,800,000. Exchange Traded Concepts LLC acquired a new position in ASP Isotopes during the 2nd quarter valued at $9,593,000. AWM Investment Company Inc. boosted its holdings in ASP Isotopes by 16.0% in the 4th quarter. AWM Investment Company Inc. now owns 4,246,186 shares of the company's stock valued at $19,235,000 after purchasing an additional 586,600 shares during the period. Two Sigma Investments LP acquired a new stake in ASP Isotopes in the 4th quarter worth $1,980,000. Finally, Nuveen Asset Management LLC increased its holdings in shares of ASP Isotopes by 672.1% during the 4th quarter. Nuveen Asset Management LLC now owns 413,346 shares of the company's stock worth $1,872,000 after purchasing an additional 359,811 shares during the period. Institutional investors own 16.80% of the company's stock.
About ASP Isotopes
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ASP Isotopes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ASP Isotopes wasn't on the list.
While ASP Isotopes currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
